Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00418002|
Recruitment Status : Completed
First Posted : January 4, 2007
Last Update Posted : June 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: AQW051||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051|
|Study Start Date :||May 2006|
- Safety and tolerability.
- Pharmacokinetics at the end of the study.
- Effect of AQW051 on cognition as assessed by a computerized cognitive test battery.
- To assess a potential food effect on pharmacokinetics of AQW051.
- To explore the drug abuse liability potential of AQW051.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00418002
|Novartis Investigative Site|
|Horsham, United Kingdom|
|Principal Investigator:||Novartis||Investigator site|